Hi, this is Yeannie! 🙋♀️🩷
This morning I had a meeting with a buyer from the US. Something they shared stuck with me, so today I wanted to pass it along to you.
This buyer had previously placed a mass production order with another manufacturer. They later discovered that the manufacturer hadn’t made their volume in one factory. The manufacturer had quietly split it across multiple facilities. As they found out, this happens more often in the industry than you’d think. That experience broke their trust completely. Ever since, they’ve made it a rule to personally tour any factory before committing to a project in Korea. They check everything along the way. And they had one clear request for us: “Please, whatever you do, don’t split production across factories.”
That conversation is exactly why a cosmetic factory audit matters before you commit to mass production. Today, let’s look at why split-site production is a real problem. Then we’ll cover what to check before you sign.
Why Cosmetic Factories Split Production Across Multiple Sites
Sometimes an order exceeds a single factory’s line capacity or equipment throughput. When that happens, some manufacturers fill the overflow through other facilities — often informal subcontractors. The issue isn’t that this happens; it’s that it usually happens without disclosure. Your contract lists one manufacturer’s name. But part of your volume may come off a line that manufacturer doesn’t actually oversee.
Yeannie’s buyer tip: Using multiple facilities isn’t automatically a red flag. The real problem is a manufacturer not disclosing it. If a manufacturer plans to use more than one site, you have every right to know in advance. Ask exactly which stage — bulk manufacturing, filling, labeling, or secondary packaging — happens where.
It’s Not Just Batch Inconsistency — Your Paperwork Falls Apart Too
Most people assume the only risk here is quality drifting between batches. In reality, the problem runs deeper than that.
Authorities issue a cosmetic GMP certificate for one specific facility address. If the certificate’s address doesn’t match the factory that made a batch, that batch falls outside what the certificate covers. The paperwork still implies a certified site made it.
For products headed to the US, this gets even more concrete. MoCRA (the Modernization of Cosmetics Regulation Act) took effect in July 2024. It requires every facility that makes or processes US-market cosmetics to register with the FDA. Each registered facility gets an FEI, or Facility Establishment Identifier, number. Every product listing then links directly to that FEI. If production actually happens at an unregistered facility, the product’s FDA listing no longer reflects reality.
Yeannie’s buyer tip: Since this buyer’s products are headed to the US, that’s the example I used. But the same structural risk shows up in most markets that require manufacturing-site declarations. That includes the EU and parts of the Middle East. This isn’t just “quality might vary a little.” It means your product could be circulating with paperwork that doesn’t match where a factory actually made it.
Cosmetic Factory Audit: What to Check Before You Sign
BeBefore signing a mass production contract, here’s what’s worth verifying:
- Does the address on the GMP certificate match the factory you’ll actually tour?
- Does the certificate’s scope cover your product type (emulsion, powder, aerosol, etc.)?
- Does it also cover the specific process you’re outsourcing — filling only, or full bulk manufacturing?
- Do you have it in writing which facility handles each stage — bulk manufacturing, filling, labeling, secondary packaging?
- If a manufacturer plans to use multiple facilities, can you get the full list of sites and addresses upfront?
Yeannie’s buyer tip: This is the exact checklist we walk buyers through during factory visits. Running through these points alone filters out most of the risk before you ever sign a contract.
How SPSCOS Handles Mass Production
At SPSCOS, we manufacture 100% of mass production volume in-house, at our own facility. We know exactly why split-site production causes problems — not just for batch consistency, but for GMP and regulatory paperwork. So we simply don’t operate that way. This isn’t something we scrambled to fix after the fact — we built our operation this way from the start. So this is one thing you genuinely don’t need to worry about with us.
That said, knowing the right ingredients, formula, and certification standards isn’t enough on its own. Holding that standard steady on the actual production line — and making sure production matches the paperwork exactly — is what buyers should expect from a manufacturing partner. If you’re curious about the formulas we’ve worked on, you can browse our formula portfolio.
If you’re wondering whether we’ll make your mass production responsibly at a single site, feel free to reach out anytime. We make sure the paperwork always matches where we actually produce it. → Get in touch
Curious what story from the floor I’ll bring next week! 🫡